We are using cookies This website uses cookies in order to offer you the most relevant information. By browsing this website, you accept these cookies.
Deregulated expression of G1 cyclins and their cognate cdk partners is often found in human tumor cells.
2
These findings argue against the proposed necessity of complete Rb inactivation by sequential phosphorylation by D- and E-type cyclin-cdk complexes.
3
We have studied the role of a conserved hydrophobic patch on the surface of cyclin A in substrate recognition by cyclin A-cdk2.
4
In addition, the concomitant expression of Np95 and of cycE-cdk2 was alone sufficient to induce S phase in TD cells.
5
Shortening of G1 phase temporally correlated with more rapid degradation of the cdk inhibitor p27Kip1 and with premature activation of cyclin A-dependent cdk2.
Usage of cyclin-dependent kinase in English
1
Purpose: Flavopiridol is the first cyclin-dependentkinase inhibitor to enter clinical trials.
2
The results implicate a putative cyclin-dependentkinase in the control of development.
3
The other three mutants caused phenotypes dependent on the particular cyclin-dependentkinase.
4
Cdc2 is the cyclin-dependentkinase that controls entry of cells into mitosis.
5
D-type cyclin-dependentkinase activities have not so far been detected in mammalian cells.
6
A major determinant of Acm1 stability is phosphorylation at consensus cyclin-dependentkinase sites.
7
Finally, the effects of cyclin-dependentkinase inhibitors on dihydrofolate reductase gene expression were evaluated.
8
The expression of cyclin-dependentkinase inhibitor p21 is dramatically increased in the mutant embryos.
9
CF neutrophils formed more NETs and this was reversed by cyclin-dependentkinase inhibitor exposure.
10
Purpose: Flavopiridol is a cyclin-dependentkinase inhibitor that prevents cell cycle progression and tumor growth.
11
Interestingly, this response was self-limited at later developmental time points by an upregulation of the cyclin-dependentkinase inhibitor p21.
12
Despite its partial structural similarity with the cyclins, p25 displays an unprecedented mechanism for the regulation of a cyclin-dependentkinase.
13
The expression of the transcription factor Sp1, a retinoblastoma-interacting protein, was also enhanced by all the cyclin-dependentkinase inhibitors tested.
14
These compounds exhibited potent inhibitory activity against cyclin-dependentkinase 4 and good antiproliferative activity in a human colon carcinoma cell line.
15
Ibrance works by blocking two enzymes, cyclin-dependentkinase 4 and 6, that are involved in cell growth.
16
Treatment with the cyclin-dependentkinase inhibitor SCH727965 alone or in combination is a highly promising novel experimental therapeutic strategy against pancreatic cancer.